BRAINSTORM CELL THERAPUTC (BCLI) is a publicly traded BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) sector company. As of July 28, 2026, BCLI trades at $1.17 with a market cap of $0 and a P/E ratio of -0.51. BCLI moved -4.10% today. Year to date, BCLI is -50.63%; over the trailing twelve months it is -80.70%. Its 52-week range spans $0.72 to $11.89. Analyst consensus is buy with an average price target of $0.00. Rallies surfaces BCLI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for BCLI combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $1.17 |
| Market Cap | $0 |
| P/E Ratio | -0.51 |
| EPS | $-2.31 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.89 |
| 52-Week Low | $0.72 |
| Volume | 2.77M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-11.62M |
| Gross Margin | 0.00% |
3 analysts cover BCLI: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $0.00.